Tabuk is currently operating through local partners in France, and has managed to further diversify its products portfolio by gaining registration approvals for three products in the cardiovascular, cephalosporin antibiotics and anti-histamines therapeutic categories, namely Amlodipine Besylate, Cefuroxime Axetil, & Cetirizine Dihydrochloride.